PCL, Inc.

KOSDAQ 241820.KQ

PCL, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2023: -40.02%

PCL, Inc. Return on Capital Employed (ROCE) is -40.02% for the year ending December 31, 2023, a -7,691.54% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

PCL, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 0.53%, a 100.61% change year over year.
PCL, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -86.87%, a -263.79% change year over year.
PCL, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 53.04%, a 194.33% change year over year.
PCL, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -56.22%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

KOSDAQ: 241820.KQ

PCL, Inc.

CEO	Ms. Soyeon Kim
IPO Date	Feb. 23, 2017
Location	South Korea
Headquarters	Star valley, 99
Employees	31
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers multiplex antibody and antigen diagnostic kits for the detection of antibodies to human immunodeficiency virus (HIV) 1 and 2, HBV, hepatitis C virus (HCV), and human T-lymphotropic virus 1 and 2, as well as antigens to HIV p24, HCV core, and HBV surface in human serum or plasma. It also provides Ai, an influenza A/B typing rapid diagnostic test kit; Cancer6, a multiple tumor markers screening kit; and sciLINER LATERAL FLOW DISPENSER, a dispenser for membrane materials with active visual drop volume control. In addition, the company offers platform services, such as sol-gel spotting service that immobilizes the customer's requested material using the SolB reagent; and SG ID service, which provides customers with a molecule of interest immobilized in the SolB reagent and identified. PCL, Inc. is headquartered in Seoul, South Korea.

Key trends

Past 5 years